


Solvent-free, under air selective synthesis of α -glycosides adopting glycosyl chlorides as the donors

Serena Traboni,* Giulia Vessella, Emiliano Bedini, and Alfonso Iadonisi*

Table of Contents


Structure and synthesis of glycosyl chlorides used in glycosylation experiments	3
Structure and synthesis of glycosyl acceptors used in glycosylation experiments	4
Spectral data of the obtained glycosides	4
References	8
Copies of ^1H and ^{13}C NMR spectra	9

Structure and synthesis of glycosyl chlorides used in glycosylation experiments



Glycosyl chlorides **1**, **S1** and **S2** were synthesized according to literature.¹

Synthesis of chloride **S3**




Scheme S1. Synthesis of chloride **S3**. Reagents and conditions: a) BzCl, pyridine, rt, 2.5 h, quantitative; b) PdCl₂, MeOH/DCM, rt, overnight, 94%; c) PPh₃, hexachloroacetone, solvent-free, 70°C, 1h, 90%.

Compound S7: To a suspension of **S5**² (122 mg, 0.305 mmol) in pyridine (123 μL, 1.52 mmol) was added benzoyl chloride (89 μL, 0.76 mmol). The reaction was stirred at room temperature for 2.5 h and then quenched by addition of MeOH. The mixture was then diluted with DCM and washed with water. The organic phase was dried over anhydrous Na₂SO₄ and concentrated under vacuum yielding crude product **S6** in quantitative yield (established by NMR analysis), which was submitted to the following reaction step without any chromatographic purification. To this aim, PdCl₂ (5.5 mg, 0.0305 mmol) was added to a solution of crude compound **S6** in MeOH / CH₂Cl₂ (4:1 v/v, 2.5 mL) and the reaction was kept under stirring overnight at room temperature. The crude mixture was concentrated under vacuum and then submitted to silica-gel chromatography to afford pure compound **S7** (163 mg, 94%, α/β 1.7:1). ¹H NMR (400 MHz, CDCl₃): δ = 8.18 – 7.27 (aromatic H), 5.95 (1H, bd, J = 2.5 Hz, H-4 α), 5.89 (1H, bd, J = 2.2 Hz, H-4 β), 5.41 (1H, d, J = 3.5 Hz, H-1α), 4.97 – 4.53 (m, overlapped, 2xAB = 2x -CH₂Ph α, 2xAB = 2x -CH₂Ph β, H-1 β, H-5 α, H-5 β, H-6a α, H-6a β), 4.42 (1H, dd, J = 6.0 Hz and 11.4 Hz, H-6b β), 4.37 (1H, dd, J = 5.8 Hz and 11.0 Hz, H-6b α), 4.17 (1H, dd, J = 3.1 Hz and 9.8 Hz, H-3α), 3.98 (1H, dd, J = 3.5 Hz and 9.8 Hz, H-2α), 3.78 – 3.74 (2H, m, overlapped, H-2β and H-3β). ¹³C NMR (100 MHz, CDCl₃): δ = 166.2, 165.8, 137.9, 133.2, 129.8 – 127.6, 97.4 (C-1β), 92.1 (C-1α), 79.8, 79.2, 75.8, 75.3, 73.6, 72.0, 71.8, 71.1, 68.4, 67.4, 66.9, 62.9. MALDI HRMS *m/z* [M+Na]⁺ Calcd for [(C₃₄H₃₂O₈+Na)⁺] 591.2097; found 591.2099; Anal. Calcd for C₃₄H₃₂O₈: C, 71.82; H, 5.67. Found C, 71.80; H, 5.64.

Compound S3: according to the above cited chlorination procedure,¹ hemiacetal **S7** (148 mg, 0.26 mmol) was weighted in a round-bottom flask and then PPh₃ (102 mg, 0.39 mmol) and hexachloroacetone (59 μL, 0.39 mmol) were sequentially added. The flask was placed in a oil bath at 70°C and kept under stirring until completion of the reaction (1h, estimated by TLC analysis). The mixture was then cooled to room temperature and then directly submitted to silica-gel chromatography to isolate pure chloride **S3** (138 mg, 90%). ¹H NMR (400 MHz, CDCl₃): δ = 8.06 – 7.26 (aromatic H), 6.22 (1H, d, J = 3.5 Hz, H-1), 5.97 (1H, bd, J = 2.9 Hz, H-4), 4.89 – 4.65 (4H, 2xAB = 2x -CH₂Ph), 4.69 (1H, bt, J = 6.5 Hz, H-5), 4.53 (1H, dd, J = 7.0 Hz and 11.7 Hz, H-6a), 4.39 (1H, dd, J = 5.7 Hz and 11.7 Hz, H-6b), 4.19 (1H, dd, J = 2.9 Hz and 9.9 Hz, H-3), 4.14 (1H, dd, J = 3.6 Hz and 9.9 Hz, H-2). ¹³C NMR (100 MHz, CDCl₃): δ = 165.9 and 165.4 (C=O), 137.6 and 137.5 (2xaromatic C = 2xPhCH₂), 133.3 and 133.2 (2x aromatic C = 2x Ph-C=O), 129.8 – 127.6 (aromatic CH), 93.9 (C-1), 75.6, 74.7, 73.3, 72.2, 70.1, 67.7, 62.3. MALDI HRMS *m/z* [M+Na]⁺ Calcd for [(C₃₄H₃₁ClO₇+Na)⁺] 609.1758; found 609.1755; Anal. Calcd for C₃₄H₃₁ClO₇: C, 69.56; H, 5.32. Found C, 69.52; H, 5.33.

Synthesis of chloride **S4**




Scheme S2. Synthesis of chloride **S4**. Reagents and conditions: a) PPh₃, hexachloroacetone, solvent-free, 70°C, 45 min, 77%.

Compound S4: according to the above cited chlorination procedure,¹ hemiacetal **S8**³ (150 mg, 0.154 mmol) was weighted in a round-bottom flask and then PPh₃ (60.7 mg, 0.23 mmol) and hexachloroacetone (35.1 μL, 0.23 mmol) were sequentially added.

The flask was placed in a oil bath at 70°C and kept under stirring until completion of the reaction (45 min, estimated by TLC analysis). The mixture was then cooled to room temperature and then directly submitted to silica-gel chromatography to isolate pure chloride **S4** (118 mg, 77%). ¹H NMR (400 MHz, CDCl₃): δ = 7.36 – 7.17 (aromatic H), 6.15 (1H, d, J = 3.8 Hz, H-1), 5.74 (1H, d, J = 3.8 Hz, H-1'), 5.09 – 4.35 (14H, 7xAB = 7x -CH₂Ph), 4.24 – 4.19 (3H, m, overlapped signals), 4.01 (1H, t, 9.6 Hz), 3.99 (1H, dd, J = 2.7 Hz and 11.4 Hz), 3.85 – 3.82 (2H, m, overlapped signals), 3.77 – 3.70 (2H, m, overlapped signals), 3.62 – 3.58 (2H, m, overlapped signals), 3.48 (1H, bd, J = 10.6 Hz). ¹³C NMR (100 MHz, CDCl₃): δ = 138.6 – 137.2 (aromatic C), 128.5 – 126.7 (aromatic CH), 96.9, 93.2 (C-1 and C-1'), 81.9, 81.2, 80.0, 79.4, 77.6, 75.5, 74.9, 74.6, 73.4, 73.3, 73.2, 73.1, 72.9, 71.6, 71.1, 68.1 (x2). MALDI HRMS *m/z* [M+Na]⁺ Calcd for [(C₆₁H₆₃ClO₁₀+Na)⁺] 1013.4110; found 1013.4114; Anal. Calcd for C₆₁H₆₃ClO₁₀: C, 73.89; H, 6.40. Found C, 73.86; H, 6.43.


Structure and synthesis of glycosyl acceptors used in glycosylation experiments




Glycosyl acceptors **2**,⁴ **S9**,⁵ **S10**,⁶ **S11**,⁷ **S12**,⁸ **S13**,⁹ **S14**,¹⁰ **S15**,¹¹ **S16**,¹² **S17**,¹³ **S18**,¹⁴ were synthesized according to literature (see pertinent references below). Cholesterol **18** is commercially available.

Spectral data of the obtained glycosides


Compound 3^[15] Colorless oil; ¹H NMR (400 MHz, CDCl₃): δ = 7.42-7.24 (benzyl aromatic protons), 7.00 (2H, J = 9.0 Hz, aryl aromatic H), 6.80 (2H, J = 9.0 Hz, aryl aromatic protons), 5.26 (1H, d, J = 3.2 Hz, H-1'), 5.11-4.29 (14H, 7 x AB, 7 x -CH₂Ph), 4.81 (1H, d, J = 7.6 Hz, H-1), 4.33 (1H, bt, J = 6.0 Hz, H-5'), 4.18 (1H, dd, J = 2.8 and 9.6 Hz, H-2'), 4.09 (1H, dd, J = 7.6 and 9.6 Hz, H-2), 4.01 (1H, bd, J = 9.9 Hz, H-3'), 3.96 (1H, bs, H-4 or H-4'), 3.87 (1H, bd, J = 9.9 Hz, H-3), 3.78 (3H, s, -OCH₃), 3.74 (1H, bs, H-4 or H-4'), 3.63-3.30 (5H, overlapped, H-5, H₂-6 and H₂-6'). ¹³C NMR (100 MHz, CDCl₃): δ = 155.0 and 151.6 (methoxyphenyl C-ipso), 138.6-138.3 (benzyl aromatic C), 128.1-127.4 (benzyl aromatic CH), 118.2, 114.3 (methoxyphenyl aromatic CH), 103.2 (C-1), 95.6 (C-1'), 79.0, 78.0, 76.3, 75.2, 74.9, 74.6, 74.3, 73.6, 73.3, 72.7, 72.4, 69.0, 55.5. MALDI HRMS *m/z* [M+Na]⁺ Calcd for [(C₆₈H₇₀O₁₂+Na)⁺] 1101.4867; found 1101.4869; Anal. Calcd for C₆₈H₇₀O₁₂: C, 75.67; H, 6.54. Found C, 75.69; H, 6.51.




Compound 6^[15] Yellowish oil; ¹H NMR (400 MHz, CDCl₃): δ = 7.39-7.14 (aromatic H), 5.52 (1H, d, J = 5.0 Hz, H-1), 5.01-4.46 (8H, 4xAB, 4xCH₂Ph), 5.01 (1H, d, J = 3.5 Hz, H-1'), 4.60 (1H, m, H-3), 4.37 (1H, dd, J = 8.0 Hz and 1.8 Hz, H-4), 4.32 (1H, dd, J = 5.0 Hz and 2.4 Hz, H-2), 4.06 (1H, t, H-5), 4.00 (1H, t, J = 9.2 Hz, H-3'), 3.86-3.65 (6H), 3.60 (1H, dd, J = 9.5 Hz and 3.6 Hz, H-2'), 1.55, 1.47, 1.34 and 1.33 (12H, 4xs, CH₃). ¹³C NMR (100 MHz, CDCl₃): δ = 138.8, 138.2(x2) and 137.8 (aromatic C), 128.2 – 127.8 (aromatic CH), 109.1 and 108.5 (-C(CH₃)₂), 96.9 and 96.2 (C-1 and C-1'), 81.9, 79.7, 75.5, 74.9, 73.4, 72.2, 70.5(x4), 70.1, 68.2, 66.1, 65.6, 25.9(x2), 24.8 and 24.5 (-C(CH₃)₂). MALDI HRMS *m/z* [M+Na]⁺ Calcd for [(C₄₆H₅₄O₁₁+Na)⁺] 805.3666; found 805.3669; Anal. Calcd for C₄₆H₅₄O₁₁: C, 70.57; H, 6.95. Found C, 70.55; H, 6.91.




Compound 7^[16] Colorless oil; ¹H NMR (400 MHz, CDCl₃): δ = 7.34 – 7.12 (aromatic H), 5.92 (1H, m, -CH=CH₂), 5.32 (1H, bd, J = 17.2 Hz, -CH=CH_{cis}H_{trans}), 5.18 (1H, bd, J = 10.2 Hz, -CH=CH_{cis}H_{trans}), 5.00 – 4.41 (14H, 7xAB, 7xCH₂Ph), 4.97 (1H, d, J = 3.3 Hz, H-1'), 4.76 (1H, d, J = 3.4 Hz, H-1), 4.18 (1H, m, CH₂=CH-CH_aH_b), 4.05 – 3.95 (3H, overlapped signals, CH₂=CH-CH_aH_b, H-3 and H-3'), 3.88 – 3.63 (7H, overlapped signals, H-5, H-5', H-6a, H-6a', H-6b, H-6b' and H-4'), 3.58 – 3.53 (2H, overlapped signals, H-2 and H-4), 3.46 (1H, dd, J = 9.6 Hz and 3.5 Hz, H-2'). ¹³C NMR (100 MHz, CDCl₃): δ = 138.7 – 137.9 (aromatic C), 133.6 (CH₂=CH-CH₂-), 128.2 – 127.5 (aromatic CH), 118.3 (CH₂=CH-CH₂-), 97.1 (C-1'), 95.1 (C-1), 82.0, 81.6, 80.0, 79.8, 77.8, 75.6, 75.4, 74.8 (x3), 73.3, 73.1, 72.3, 70.4, 70.1, 68.3, 67.9 and 65.9 (CH₂=CH-CH₂-, C-6 and C-6'). MALDI HRMS *m/z* [M+Na]⁺ Calcd for ([C₆₁H₆₃O₁₀+Na]⁺) 1035.4762; found 1035.4766; Anal. Calcd for C₆₁H₆₃O₁₀: C, 76.63; H, 6.64. Found C, 76.68; H, 6.61.




Compound 8^[17] Colorless oil; ¹H NMR (400 MHz, CDCl₃): δ = 7.37 – 7.18 (aromatic H), 5.20 (1H, d, J = 1.6 Hz, H-1'), 4.89 – 4.84 (2H, 1xAB, CH₂Ph), 4.80 (1H, d, J = 1.5 Hz, H-1), 4.70 – 4.48 (12 H, 6xAB, 6x CH₂Ph), 4.08 (1H, bs, H-2 or H-2'), 3.94-3.89 (4H, m, overlapped signals), 3.83 (1H, bs, H-2 or H-2'), 3.79 – 3.70 (6H, m, overlapped signals), 3.26 (3H, s, -OCH₃). ¹³C NMR (100 MHz, CDCl₃): δ = 138.5 – 138.3 (aromatic C), 128.1-127.3 (aromatic CH), 99.8 and 99.4 (C-1 and C-1'), 79.9, 79.6, 74.9(x5), 74.1, 73.2(x2), 72.3, 72.1(x3), 71.6, 69.4 and 69.3 (C-6 and C-6'), 54.6 (-OCH₃). MALDI HRMS *m/z* [M+Na]⁺ Calcd for ([C₆₂H₆₆O₁₁+Na]⁺) 1009.4605; found 1009.4610; Anal. Calcd for C₆₂H₆₆O₁₁: C, 75.43; H, 6.74. Found C, 75.49; H, 6.76.




Compound 9 Yellowish oil; ¹H NMR (400 MHz, CDCl₃): δ = 7.40 – 7.17 (aromatic H), 5.96 (1H, m, -CH=CH₂), 5.35 (1H, bd, J = 17.2 Hz, -CH=CH_{cis}H_{trans}), 5.20 (1H, bd, J = 10.4 Hz, -CH=CH_{cis}H_{trans}), 5.14 (1H, bs, H-1'), 4.93 – 4.48 (13 H, 6xAB = 6x CH₂Ph and H-1), 4.11 (2H, m, CH₂=CH-CH_aH_b and CH₂=CH-CH_aH_b), 4.04 (1H, t, J = 10.0 Hz, H-4 or H-4'), 3.95 – 3.72 (9 H, m, overlapped signals, H-2, H-2', H-3, H-3', H-4 or H-4', H-6a, H-6a', H-6b, H-6b'), 3.68 – 3.63 (2H, m, overlapped signals, H-5 and H-5'), 3.26 (3H, s, -OCH₃). ¹³C NMR (100 MHz, CDCl₃): δ = 138.6 – 138.3 (aromatic C), 134.8 (CH₂=CH-CH₂-), 128.2 – 127.3 (aromatic CH), 116.5 (CH₂=CH-CH₂-), 98.9 and 97.9 (C-1 and C-1'), 79.9, 79.3, 74.9(x5), 74.4, 73.1, 72.7, 72.3, 71.7, 71.4, 71.3, 70.9, 69.1, 65.9, 54.5 (-OCH₃). MALDI HRMS *m/z* [M+Na]⁺ Calcd for ([C₅₈H₆₄O₁₁+Na]⁺) 959.4449; found 959.4451; Anal. Calcd for C₅₈H₆₄O₁₁: C, 74.34; H, 6.88. Found C, 74.29; H, 6.90.




Compound 10^[9] Yellowish oil; ¹H NMR (400 MHz, CDCl₃): δ = 7.43 – 7.16 (aromatic H), 5.00 (1H, d, J = 3.4 Hz, H-1'), 4.73 (1H, d, J = 3.2 Hz, H-1), 4.91 – 4.53 (14H, 7xAB = 7x CH₂Ph), 4.41 (1H, bdd, J = 4.1 Hz and 9.7 Hz), 4.23 (1H, bs), 4.11 (2H, bs), 4.07 (1H, bd, J = 9.0 Hz), 3.94 – 3.81 (4H, m), 3.57 – 3.48 (2H, m), 3.36 (3H, s, -OCH₃), 3.22 (1H, dd, J = 4.6 Hz and 8.2 Hz). ¹³C NMR (100 MHz, CDCl₃): δ = 138.8 – 138.0 (aromatic C), 128.1 – 127.4 (aromatic CH), 100.2 and 98.7 (C-1 and C-1'), 79.4, 77.9, 76.2, 74.9, 74.8, 74.5, 74.0, 73.2(x2), 73.1, 72.8, 72.5, 72.1, 69.4, 69.1, 68.0, 67.7, 55.2. MALDI HRMS *m/z* [M+Na]⁺ Calcd for ([C₆₂H₆₆O₁₁+Na]⁺) 1009.4605; found 1009.4608; Anal. Calcd for C₆₂H₆₆O₁₁: C, 75.43; H, 6.74. Found C, 75.46; H, 6.68.



Compound 11^[18] Colorless oil; ¹H NMR (400 MHz, CDCl₃): δ = 7.42-6.94 (aromatic H), 5.61 (1H, d, J = 3.6 Hz, H-1'), 5.48 (1H, s, benzylidene -CHPh), 5.03 – 4.33 (11H, 5xAB = 5xCH₂Ph and H-1), 4.28 – 4.21 (2H, m, overlapped signals, H-6eq and H-5'), 4.00 (1H, t, J = 9.3 Hz, H-3), 3.89 (1H, m, H-5), 3.80 (1H, bt, J = 9.3 Hz, H-6ax), 3.73 (1H, t, J = 10.0 Hz, H-3'), 3.70 – 3.65 (2H, m, overlapped signals, H-2 and H-4'), 3.50 – 3.47 (4H, overlapped signals, H₂-6', H-4 and H-2'), 3.43 (3H, s, -OCH₃). ¹³C NMR (100 MHz, CDCl₃): δ = 138.8(x2), 137.9, 137.7, 137.3 and 136.9 (aromatic C), 129.3-126.3 (aromatic CH), 102.0, 98.4 and 96.0 (acetal CH), 82.8, 81.6, 78.7, 77.9, 75.4, 74.7, 73.3 (x3), 72.6, 71.0, 69.7, 69.1, 68.0, 61.7, 55.2. MALDI HRMS *m/z* [M+Na]⁺ Calcd for ([C₅₅H₅₈O₁₁+Na]⁺) 917.3979; found 917.3982; Anal. Calcd for C₅₅H₅₈O₁₁: C, 73.81; H, 6.53. Found C, 73.83; H, 6.51.




Compound 12 Colorless oil; ¹H NMR (400 MHz, CDCl₃): δ = 7.71 – 6.81 (aromatic H), 5.59 (1H, d, J = 3.5 Hz, H-1'), 5.48 (1H, d, J = 10.5 Hz, H-1), 5.44 (1H, s, benzylidene -CHPh), 4.92 – 4.11 (11H, overlapped signals), 3.94 (1H, m), 3.81 – 3.78 (2H, m, overlapped signals), 3.70 (1H, t, J = 9.5 Hz), 3.41 (1H, t, J = 9.9 Hz), 3.34 (1H, dd, J = 3.3 Hz and 9.5 Hz, H-2'), 3.01 – 2.93 (2H, m), 2.75 – 2.63 (3H, m), 1.21 (3H, t, J = 7.4 Hz, -SCH₂CH₃). ¹³C NMR (100 MHz, CDCl₃): δ = 167.9 and 167.6 (C=O), 138.8 – 122.8 (aromatic signals), 101.8 (PhCH), 96.3 (C-1'), 83.0 (C-1), 81.6, 80.8, 78.4, 75.4, 73.9, 73.3(x2), 72.6, 71.2, 70.6, 70.0, 68.7, 67.1, 53.9 (C-2), 23.8 (-SCH₂CH₃), 14.7 (-SCH₂CH₃). MALDI HRMS *m/z* [M+Na]⁺ Calcd for ([C₅₇H₅₇NO₁₁S+Na]⁺) 986.3652; found 986.3656; Anal. Calcd for C₅₇H₅₇NO₁₁S: C, 71.01; H, 5.96. Found C, 71.04; H, 5.91.




Compound 13^[19] Colorless oil; ¹H NMR (400 MHz, CDCl₃): δ = 7.82 – 6.99 (aromatic H), 5.59 (1H, d, J = 3.7 Hz, H-1'), 5.43 (1H, d, J = 10.7 Hz, H-1), 5.40 (1H, s, benzylidene -CHPh), 4.92 (1H, t, J = 9.7 Hz), 4.86 – 4.25 (8H, 4xAB = 4xCH₂Ph), 3.93 – 3.88 (4H, m, overlapped signals), 3.80 – 3.76 (3H, m, overlapped signals), 3.66 (1H, bs, H-4'), 4.41 (1H, m), 3.29 (1H, t, J = 9.0 Hz), 2.87 (1H, m), 2.76 – 2.64 (2H, m, -SCH₂CH₃), 1.19 (3H, t, J = 7.4 Hz, -SCH₂CH₃). ¹³C NMR

(100 MHz, CDCl₃): δ = 167.9 and 167.6 (C=O), 138.9 – 122.9 (aromatic signals), 101.6 (PhCH), 97.3 (C-1'), 82.9 (C-1), 81.6, 77.9, 75.3, 74.7(x2), 73.2(x2), 72.7, 71.6, 70.0, 69.3, 68.9, 67.7, 54.1(C-2), 23.9 (-SCH₂CH₃), 14.8(-SCH₂CH₃). MALDI HRMS *m/z* [M+Na]⁺ Calcd for [(C₅₇H₅₇NO₁₁S+Na)⁺] 986.3652; found 986.3655; Anal. Calcd for C₅₇H₅₇NO₁₁S: C, 71.01; H, 5.96. Found C, 71.02; H, 5.90.




Compound 14 Yellowish oil; ¹H NMR (400 MHz, CDCl₃): δ = 8.10 – 7.14 (aromatic H), 5.71 – 5.61 (2H, m, overlapped signals, -CH=CH₂ and H-4), 5.52 (1H, dd, J = 1.8 and 3.2 Hz, H-2), 5.15 (1H, bd, J = 17.2 Hz, -CH=CH_{cis}H_{trans}), 5.03 (1H, bd, J = 10.4 Hz, -CH=CH_{cis}H_{trans}), 4.94 (1H, bs, H-1'), 4.86 (1H, bs, H-1), 4.85 – 4.30 (8H, 4xAB = 4x -CH₂Ph), 4.11 – 4.06 (3H, m, overlapped signals, CH₂=CH-CH_aH_b and H-3), 4.03 – 3.89 (5H, m, overlapped signals, H-2', H-4', H-5, H-6a and H-6b), 3.84 (1H, dd, J = 3.2 Hz and 9.7 Hz, H-3'), 3.75 – 3.68 (4H, m, overlapped signals, H-5', H-6a' and H-6b'), 3.38 (3H, s, -OCH₃). ¹³C

NMR (100 MHz, CDCl₃): δ = 165.7 and 165.2 (2xC=O), 138.5, 138.4, 138.3 and 138.2 (4xaromatic C = 4xPhCH₂), 134.2 (CH₂=CH-CH₂-), 133.2 and 133.0 (2x aromatic C = 2x Ph-C=O), 129.9 – 127.2 (aromatic CH), 117.3 (CH₂=CH-CH₂-), 98.7 and 97.8 (C-1 and C-1'), 80.1, 74.9, 74.6(x2), 74.3, 73.1, 72.3, 71.8, 71.7, 70.7, 69.5, 69.3, 68.9(x2), 66.9, 55.1 (-OCH₃). MALDI HRMS *m/z* [M+Na]⁺ Calcd for [(C₅₈H₆₀O₁₃+Na)⁺] 987.4034; found 987.4039; Anal. Calcd for C₅₈H₆₀O₁₃: C, 72.18; H, 6.27. Found C, 72.13; H, 6.21.




Compound 15 Colorless oil; ¹H NMR (400 MHz, CDCl₃): δ = 8.04 – 7.24 (aromatic H), 5.93 (1H, d, J = 3.2 Hz, H-4'), 5.51 (1H, d, J = 5.0 Hz, H-1), 5.07 (1H, d, J = 3.5 Hz, H-1'), 4.87 – 4.61 (4H, 2xAB = 2x -CH₂Ph), 4.58 (1H, dd, J = 2.3 Hz and 8.0 Hz, H-3), 4.54 – 4.48 (2H, m, overlapped signals, H-6a' and H-6b'), 4.35 – 4.28 (3H, m, overlapped signals, H-2, H-4 and H-5'), 4.16 (1H, dd, J = 3.2 Hz and 9.9 Hz, H-3'), 4.05 (1H, m, H-5), 3.96 (1H, dd, J = 3.5 Hz and 9.9 Hz, H-2'), 3.88 – 3.81 (2H, m, overlapped signals, H-6a and H-6b), 1.51, 1.40, 1.32 and 1.29 (12H, 4xs, -CH₃). ¹³C NMR (100 MHz, CDCl₃): δ = 166.0 and 165.7 (2xC=O), 138.2 and 138.0 (2xaromatic C = 2xPhCH₂), 133.0 and 132.9 (2x aromatic C = 2x Ph-C=O), 129.6 – 127.3 (aromatic CH), 109.1

and 108.4 (-C(CH₃)₂), 97.9 and 96.2 (C-1 and C-1'), 76.0, 75.1, 73.1, 71.9, 70.9, 70.6, 70.4, 68.6, 67.2, 66.9, 66.5, 63.0, 25.9(x2), 24.8, 24.4 (-C(CH₃)₂). MALDI HRMS *m/z* [M+Na]⁺ Calcd for [(C₄₆H₅₀O₁₃+Na)⁺] 833.3251; found 833.3256; Anal. Calcd for C₄₆H₅₀O₁₃: C, 68.13; H, 6.22. Found C, 68.08; H, 6.21.




Compound 16 Colorless oil; ¹H NMR (400 MHz, CDCl₃): δ = 8.03 – 6.80 (aromatic H), 5.36 (1H, bs, H-4'), 5.23 (1H, bs, H-1'), 5.14 – 4.24 (14H, overlapped signals, 5x AB = 5x -CH₂Ph, H-1, H-5' and H-2-6'), 4.11 (1H, dd, J = 7.6 Hz and 10.0 Hz, H-2), 4.02 (2H, bs), 3.92 – 3.89 (2H, m, overlapped signals), 3.85 (1H, dd, J = 2.4 Hz and 9.9 Hz, H-3), 3.80 (3H, s, -OCH₃), 3.61 – 3.55 (2H, m,

overlapped signals, H₂-6a and H₂-6b), 3.50 (1H, bt, J = 6.2 Hz, H-5). ¹³C NMR (100 MHz, CDCl₃): δ = 165.7 and 165.6 (C=O), 155.0 and 151.6 (methoxyphenyl C-ipso), 138.7-137.9 (benzyl aromatic C), 133.0 and 132.8 (benzoyl aromatic C), 129.8 – 127.3 (aromatic CH), 118.2 and 114.4 (methoxyphenyl aromatic CH), 103.6 (C-1), 94.7 (C-1'), 77.9, 75.4, 74.6, 74.4(x4), 73.6, 73.4, 71.7(x2), 71.5, 68.7, 67.2, 63.6, 55.6. MALDI HRMS *m/z* [M+Na]⁺ Calcd for [(C₆₈H₆₆O₁₄+Na)⁺] 1129.4453; found 1129.4454; Anal. Calcd for C₆₈H₆₆O₁₄: C, 73.76; H, 6.01. Found C, 73.70; H, 5.98.




Compound 17 Colorless oil; ¹H NMR (400 MHz, CDCl₃): δ = 7.31 – 7.12 (aromatic H), 5.73 (1H, d, J = 3.4 Hz, H-1 C), 5.55 (1H, d, J = 5.2 Hz, H-1 A), 5.09 – 4.28 (15 H, 7xAB = 7x-CH₂Ph and H-3 A), 5.04 (1H, d, J = 3.4 Hz, H-1 B), 4.40 (1H, dd, J = 1.7 Hz and 8.0 Hz, H-4 A), 4.35 (1H, dd, J = 2.4 Hz and 5.0 Hz, H-2 A), 4.14 – 4.10 (3H, m, overlapped signals), 3.99 – 3.90 (3H, m, overlapped signals), 3.83 – 3.77 (3H, m, overlapped signals), 3.72 – 3.66 (3H, m, overlapped signals), 3.53 (2H, bdd, J = 3.5 Hz and 10.0 Hz, H-2 B and H-2 C), 3.41 (1H, bd, J = 10.6 Hz), 1.60, 1.49, 1.35 and 1.34 (12H, 4xs, CH₃). ¹³C

NMR (100 MHz, CDCl₃): δ = 138.9 – 137.9 (aromatic C), 128.2 – 126.7 (aromatic CH), 109.1 and 108.6 (-C(CH₃)₂), 96.5 (x2) and 96.2 (C-1 A, C-1 B and C-1 C), 81.9, 81.7, 79.8, 79.4, 77.6, 75.4, 74.8, 74.1, 73.4, 73.0 (x2), 72.2, 72.1, 70.8 (x2), 70.6 (x2), 69.6, 68.8, 68.1, 66.2, 65.7, 26.1, 26.0, 24.8 and 24.6 (-C(CH₃)₂). MALDI HRMS *m/z* [M+Na]⁺ Calcd for [(C₆₆H₇₅O₁₅+Na)⁺] 1237.5603; found 1237.5607; Anal. Calcd for C₆₆H₇₅O₁₅: C, 71.52; H, 6.82. Found C, 71.56; H, 6.85.




Compound 19^[20] Yellowish oil; ¹H NMR (400 MHz, CDCl₃): δ = 7.41 – 7.26 (aromatic H), 5.00 (1H, d, J = 3.7 Hz, H-1), 4.97 – 4.39 (8H, 4xAB = 4x -CH₂Ph), 4.06 (1H, bt, J = 6.5 Hz, cholesterol-H-3), 4.01 (1H, dd, J = 3.6 Hz and 9.6 Hz, H-2), 3.97 – 3.94 (2H, m, overlapped signals, H-4 and H-3), 3.59 – 3.51 (3H, m, overlapped signals, H-5, H-6a and H-6b), 1.99 – 0.56 (m, overlapped signals, cholesterol backbone H). ¹³C NMR (100 MHz, CDCl₃): δ = 138.9 – 138.6 (aromatic C), 128.2 – 127.4 (aromatic CH), 95.4 (C-1), 79.1, 76.2, 75.2, 74.6, 73.3, 73.1, 73.0,

69.2, 56.4, 56.2, 54.2, 45.0 – 11.9. MALDI HRMS m/z [M+Na]⁺ Calcd for [(C₆₁H₈₂O₆+Na)⁺] 933.6111; found 933.6117; Anal. Calcd for C₆₁H₈₂O₆: C, 80.40; H, 9.07. Found C, 80.37; H, 9.01.




Compound 21^[21] Colorless oil; ¹H NMR (400 MHz, CDCl₃): δ = 7.42 – 7.26 (aromatic H), 5.00 – 4.65 (6H, 3xAB = 3x -CH₂Ph), 4.96 (1H, d, J = 3.7 Hz, H-1), 4.01 (1H, dd, J = 3.7 Hz and 10.0 Hz, H-2), 3.95 (1H, m, H-5), 3.94 (1H, dd, J = 2.8 Hz and 10.0 Hz, H-3), 3.66 (1H, bs, H-4), 3.48 (1H, m, cholesterol-H-3), 1.99 – 0.56 (m, overlapped signals, cholesterol backbone), 1.10, 0.91, 0.88, 0.87 (12H, 4xd, J = 6.50 Hz, 4x -CH₃), 0.81 and 0.66 (6H, 2xs, 2x -CH₃). ¹³C NMR (100 MHz, CDCl₃): δ = 139.0 – 138.6 (aromatic C), 128.2 – 127.3 (aromatic CH), 95.3 (C-1), 79.4, 77.8, 76.0, 74.7, 73.2,

72.9, 65.9, 56.4, 56.2, 54.3, 44.7 – 11.9. MALDI HRMS m/z [M+Na]⁺ Calcd for [(C₅₄H₇₆O₅+Na)⁺] 827.5693; found 827.5697; Anal. Calcd for C₅₄H₇₆O₅: C, 80.55; H, 9.51. Found C, 80.52; H, 9.49.



Compound 22 Yellowish oil; ¹H NMR (400 MHz, CDCl₃): δ = 7.38 – 7.02 (aromatic H), 5.83 (1H, m, -CH=CH₂), 5.67 (1H, d, J = 3.8 Hz, H-1'), 5.21 (1H, bd, J = 17.2 Hz, -CH=CH_{cis}H_{trans}), 5.09 (1H, bd, J = 10.7 Hz, -CH=CH_{cis}H_{trans}), 4.95 – 4.33 (14 H, m, overlapped signals, 6xAB = 6x -CH₂Ph, H-1 and CH₂=CH-CH_aH_b), 4.24 (1H, dd, J = 7.8 Hz and 9.8 Hz, H-2), 4.03 (1H, dd, J = 3.8 Hz and 10.0 Hz, H-2'), 4.02 (1H, m, -CH₂=CH-CH_aH_b), 3.95 – 3.92 (2H, m, overlapped signals, H-5' and H-3'), 3.73 (1H, dd, J = 2.4 Hz and 9.9 Hz, H-3), 3.63 – 3.57 (5H, m, overlapped signals, H-4, H-4', H-5, H₂-6), 1.10 (3H, d, J = 6.5 Hz, -CH₃). ¹³C NMR

(100 MHz, CDCl₃): δ = 138.8 – 137.8 (aromatic C), 134.1 (CH₂=CH-CH₂-), 128.2 – 126.2 (aromatic CH), 117.2 (CH₂=CH-CH₂-), 101.0 (C-1), 97.1 (C-1'), 84.2, 79.4, 78.0, 75.5, 74.6, 74.2, 73.5, 73.2, 72.8, 72.4, 72.2, 71.8, 71.1, 69.9, 68.7, 66.2, 16.4 (-CH₃). MALDI HRMS m/z [M+Na]⁺ Calcd for [(C₅₇H₆₂O₁₀+Na)⁺] 929.4343; found 929.4345; Anal. Calcd for C₅₇H₆₂O₁₀: C, 75.47; H, 6.89. Found C, 75.43; H, 6.91.





Compound 23 Yellowish oil; ¹H NMR (400 MHz, CDCl₃): δ = 7.41 – 7.26 (aromatic H), 5.88 (1H, m, -CH=CH₂), 5.49 (1H, t, J = 9.8 Hz, H-3 Glc), 5.33 (1H, d, J = 3.0 Hz, H-4 Gal), 5.29 (1H, bd, J = 17.0 Hz, -CH=CH_{cis}H_{trans}), 5.17 (1H, bd, J = 10.7 Hz, -CH=CH_{cis}H_{trans}), 5.12 (1H, dd, J = 8.0 Hz and 10.0 Hz, H-2 Gal), 4.99 – 4.93 (3H, m, overlapped signals, H-1 Fuc, H-1 Glc and H-3 Gal), 4.85 – 4.59 (6H, 3xAB = 3x -CH₂Ph), 4.53 (1H, d, J = 7.8 Hz, H-1 Gal), 4.37 (1H, bd, J = 11.6 Hz, H-6a Glc), 4.16 – 4.03 (6H, m, overlapped signals, CH₂=CH-CH_aH_b, H-6b Glc, H₂-6 Gal and H-2 Glc), 3.96 – 3.83 (4H, m, overlapped


signals, H-5 Gal, H-5 Glc, H-2 Fuc and H-5 Fuc), 3.72 (1H, t, J = 9.5 Hz, H-4 Glc), 3.59 (1H, bs, H-4 Fuc), 3.46 (1H, dd, J = 3.1 Hz and 10.0 Hz, H-3 Fuc), 2.14, 2.12, 2.04, 2.03, 1.96 and 1.78 (18H, 6xs, 6x -COCH₃), 1.03 (3H, d, J = 6.5 Hz, -CH₃ Fuc). ¹³C NMR (100 MHz, CDCl₃): δ = 170.4, 171.1 (x3), 169.5 and 168.9 (C=O), 138.8, 138.6 and 138.5 (aromatic C), 133.3 (CH₂=CH-CH₂-), 128.2 – 127.4 (aromatic CH), 117.5 (CH₂=CH-CH₂-), 100.7 (x2) and 97.2 (C-1 Gal, C-1 Glc and C-1 Fuc), 79.7, 78.9, 77.8, 76.3, 74.7, 73.3, 73.1, 71.0, 70.3, 70.1, 69.0, 68.9, 67.9, 67.1, 66.4, 62.2, 60.5(x2), 20.5(x6 CH₃C=O), 16.6 (-CH₃). MALDI HRMS m/z [M+Na]⁺ Calcd for [(C₅₄H₆₆O₂₁+Na)⁺] 1073.4097; found 1073.4100; Anal. Calcd for C₅₄H₆₆O₂₁: C, 61.71; H, 6.33. Found C, 61.74; H, 6.29.



References


- 1) S. Traboni, F. Liccardo, E. Bedini, M. Giordano and A. Iadonisi, *Tetrahedron Lett.*, 2017, **58**, 1762.
- 2) P. Chassagne, C. Fontana, C. Guerreiro, C. Gauthier, A. Phalipon, G. Widmalm and L. A Mulard, *Eur. J. Org. Chem.*, 2013, 4085.
- 3) B. Liu, J. Van Mechelen, R. J. B. H. N. van der Berg, A. M. C. H. van der Nieuwendijk, J. M. F. G. Aerts, G. A. van der Marel, J. D. C. Codée and H. S. Overkleeft, *Eur. J. Org. Chem.*, 2019, 118.
- 4) M. Adinolfi, A. Iadonisi, A. Ravidà and M. Schiattarella, *J. Org. Chem.*, 2005, **70**, 5316.
- 5) P. Besenius, S. Slavin, F. Vilela and D. C. Sherrington, *Reactive & Functional Polymers*, 2008, **68**, 1524.
- 6) S. Hanashima, Y. Mizushina, T. Yamazaki, K. Ohta, S. Takahashi, H. Sahara, K. Sakaguchi and F. Sugawara, *Bioorg. Med. Chem.*, 2001, **9**, 367.
- 7) J. Beignet, J. Tiernan, C. H. Woo, B. M. Kariuki and L. R. Cox, *J. Org. Chem.*, 2004, **69**, 6341.
- 8) M. Neralkar, B. Mishra and S. Hotha, *J. Org. Chem.*, 2017, **82**, 11494.
- 9) A. Pastore, S. Valerio, A. Adinolfi and A. Iadonisi, *Chem. Eur. J.*, 2011, **17**, 5881.
- 10) H. Xu, Y. Lu, Y. Zhou, B. Ren, Y. Pei, H. Dong and Z. Pei, *Adv. Synth. Catal.*, 2014, **356**, 1735.
- 11) S. Traboni, E. Bedini, M. Giordano and A. Iadonisi, *Adv. Synth. Catal.*, 2015, **357**, 3562.
- 12) S. Traboni, E. Bedini and A. Iadonisi, *ChemistrySelect*, 2018, **3**, 1616.
- 13) D. Somasundaran, K. K. Balasubramanain and B. Shanmugasundaram, *Tetrahedron Lett.*, 2019, **60**, 764.
- 14) A. Pastore, M. Adinolfi and A. Iadonisi, *Eur. J. Org. Chem.*, 2008, 6206.
- 15) M. Adinolfi, A. Iadonisi, A. Ravidà and M. Schiattarella, *Tetrahedron Lett.*, 2004, **45**, 4485.
- 16) P. Wang, P. Haldar, Y. Wang and H. Hu, *J. Org. Chem.*, 2007, **72**, 5870.
- 17) G. X. Chang and T. L. Lowary, *Org. Lett.*, 2000, **2**, 1505.
- 18) L. Sun, X. Wu, D.-C. Xiong and X.-S. Ye, *Angew. Chem. Int. Ed.*, 2016, **55**, 8041.
- 19) A. Sau and A. K. Misra, *Beilstein J. Org. Chem.*, 2012, **8**, 2053.
- 20) T. Mukaiyama, K. Matsubara, and M. Hora, *Synthesis*, 1994, 1368.
- 21) K. Higashi and H. Susaki, *Chem. Pharm. Bull.*, 1992, **40**, 2019.



Copies of ^1H and ^{13}C NMR spectra





















3












9

















8















10










11










12












13















15












16















19










21









22







23

